https://www.selleckchem.com/pr....oducts/8-oh-dpat-8-h
We found no difference in mortality between angiosarcomas and other PCS subtypes. Overall, surgery was found to provide a significant mortality advantage to PCS patients up to 3 years following treatment. Multimodality treatment might be of additional benefit, although only within the first year. Prospective randomized studies are needed to further explore these differences in the treatment of PCS. Overall, surgery was found to provide a significant mortality advantage to PCS patients up to 3 years following treatment.
Like
Comment
Share
